Biotech Values

[jbog]

Teva and Lonza announce decision to discontinue biologics joint venture

Teva Pharmaceutical and Lonza Group announced that following a strategic review of the Teva-Lonza Joint Venture, the companies have decided to discontinue their collaboration for the development, manufacturing and marketing of biosimilars. The companies said that the discontinuation of the TL-JV will enable both companies to better advance their own strategies and efforts in serving those healthcare communities. Both companies said they will continue to explore opportunities to maximize the value of the investments and progress that the joint venture has made to this point, and remain in agreement that affordable, efficacious and safe biosimilar treatments will bring benefits to patients and better serve these communities.